Distinct Host Cell Fates for Human Malignant Melanoma Targeted by Oncolytic Rodent Parvoviruses

Overview

Journal Virology

Specialty Microbiology

Date 2013 Oct 1

PMID 24074565

Citations 5

Authors

Ellen M Vollmers

Peter Tattersall

Affiliations

Soon will be listed here.

Abstract

The rodent parvoviruses are known to be oncoselective, and lytically infect many transformed human cells. Because current therapeutic regimens for metastatic melanoma have low response rates and have little effect on improving survival, this disease is a prime candidate for novel approaches to therapy, including oncolytic parvoviruses. Screening of low-passage, patient-derived melanoma cell lines for multiplicity-dependent killing by a panel of five rodent parvoviruses identified LuIII as the most melanoma-lytic. This property was mapped to the LuIII capsid gene, and an efficiently melanoma tropic chimeric virus shown to undergo three types of interaction with primary human melanoma cells: (1) complete lysis of cultures infected at very low multiplicities; (2) acute killing resulting from viral protein synthesis and DNA replication, without concomitant expansion of the infection, due to failure to export progeny virions efficiently; or (3) complete resistance that operates at an intracellular step following virion uptake, but preceding viral transcription.

Citing Articles

H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.

Bretscher C, Marchini A Viruses. 2019; 11(6).

PMID: 31216641 PMC: 6630270. DOI: 10.3390/v11060562.

Optimizing the Targeting of Mouse Parvovirus 1 to Murine Melanoma Selects for Recombinant Genomes and Novel Mutations in the Viral Capsid Gene.

Marr M, DAbramo A, Pittman N, Agbandje-Mckenna M, Cotmore S, Tattersall P Viruses. 2018; 10(2).

PMID: 29385689 PMC: 5850361. DOI: 10.3390/v10020054.

Atomic Resolution Structure of the Oncolytic Parvovirus LuIII by Electron Microscopy and 3D Image Reconstruction.

Pittman N, Misseldine A, Geilen L, Halder S, Smith J, Kurian J Viruses. 2017; 9(11).

PMID: 29084163 PMC: 5707528. DOI: 10.3390/v9110321.

Genome sequence of tumor virus x, a member of the genus protoparvovirus in the family parvoviridae.

Vollmers E, DAbramo Jr A, Cotmore S, Tattersall P Genome Announc. 2014; 2(4).

PMID: 25081268 PMC: 4118071. DOI: 10.1128/genomeA.00758-14.

Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.

Angelova A, Grekova S, Heller A, Kuhlmann O, Soyka E, Giese T J Virol. 2014; 88(10):5263-76.

PMID: 24574398 PMC: 4019131. DOI: 10.1128/JVI.03688-13.

References

Paradiso P . Infectious process of the parvovirus H-1: correlation of protein content, particle density, and viral infectivity. J Virol. 1981; 39(3):800-7. PMC: 171312. DOI: 10.1128/JVI.39.3.800-807.1981. View

Tworkoski K, Singhal G, Szpakowski S, Zito C, Bacchiocchi A, Muthusamy V . Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol Cancer Res. 2011; 9(6):801-12. PMC: 3117976. DOI: 10.1158/1541-7786.MCR-10-0512. View

Prestwich R, Harrington K, Pandha H, Vile R, Melcher A, Errington F . Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther. 2008; 8(10):1581-8. PMC: 2729453. DOI: 10.1586/14737140.8.10.1581. View

Cotmore S, Tattersall P . Genome packaging sense is controlled by the efficiency of the nick site in the right-end replication origin of parvoviruses minute virus of mice and LuIII. J Virol. 2005; 79(4):2287-300. PMC: 546602. DOI: 10.1128/JVI.79.4.2287-2300.2005. View

Bloom M, Berry B, Wei W, Perryman S, Wolfinbarger J . Characterization of chimeric full-length molecular clones of Aleutian mink disease parvovirus (ADV): identification of a determinant governing replication of ADV in cell culture. J Virol. 1993; 67(10):5976-88. PMC: 238019. DOI: 10.1128/JVI.67.10.5976-5988.1993. View

Lang S, Giese N, Rommelaere J, Dinsart C, Cornelis J . Humoral immune responses against minute virus of mice vectors. J Gene Med. 2006; 8(9):1141-50. DOI: 10.1002/jgm.940. View

Moehler M, Blechacz B, Weiskopf N, Zeidler M, Stremmel W, Rommelaere J . Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. Cancer Gene Ther. 2001; 8(3):158-67. DOI: 10.1038/sj.cgt.7700288. View

Cornelis J, Chen Y, Spruyt N, Duponchel N, Cotmore S, Tattersall P . Susceptibility of human cells to killing by the parvoviruses H-1 and minute virus of mice correlates with viral transcription. J Virol. 1990; 64(6):2537-44. PMC: 249429. DOI: 10.1128/JVI.64.6.2537-2544.1990. View

Cotmore S, Tattersall P . Encapsidation of minute virus of mice DNA: aspects of the translocation mechanism revealed by the structure of partially packaged genomes. Virology. 2005; 336(1):100-12. DOI: 10.1016/j.virol.2005.03.007. View

10.

DAbramo Jr A, Ali A, Wang F, Cotmore S, Tattersall P . Host range mutants of Minute Virus of Mice with a single VP2 amino acid change require additional silent mutations that regulate NS2 accumulation. Virology. 2005; 340(1):143-54. DOI: 10.1016/j.virol.2005.06.019. View

11.

Raykov Z, Grekova S, Galabov A, Balboni G, Koch U, Aprahamian M . Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model. Oncol Rep. 2007; 17(6):1493-9. View

12.

Farr G, Tattersall P . A conserved leucine that constricts the pore through the capsid fivefold cylinder plays a central role in parvoviral infection. Virology. 2004; 323(2):243-56. DOI: 10.1016/j.virol.2004.03.006. View

13.

Gardiner E, Tattersall P . Evidence that developmentally regulated control of gene expression by a parvoviral allotropic determinant is particle mediated. J Virol. 1988; 62(5):1713-22. PMC: 253210. DOI: 10.1128/JVI.62.5.1713-1722.1988. View

14.

Bakkouri K, Servais C, Clement N, Cheong S, Franssen J, Velu T . In vivo anti-tumour activity of recombinant MVM parvoviral vectors carrying the human interleukin-2 cDNA. J Gene Med. 2004; 7(2):189-97. DOI: 10.1002/jgm.653. View

15.

Ravnan M, Matalka M . Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin Ther. 2012; 34(7):1474-86. DOI: 10.1016/j.clinthera.2012.06.009. View

16.

Wetzel K, Struyf S, Van Damme J, Kayser T, Vecchi A, Sozzani S . MCP-3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells. Int J Cancer. 2006; 120(6):1364-71. DOI: 10.1002/ijc.22421. View

17.

Gupta P, Kuperwasser C, Brunet J, Ramaswamy S, Kuo W, Gray J . The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet. 2005; 37(10):1047-54. PMC: 1694635. DOI: 10.1038/ng1634. View

18.

Hocker T, Singh M, Tsao H . Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol. 2008; 128(11):2575-2595. DOI: 10.1038/jid.2008.226. View

19.

Mincberg M, Gopas J, Tal J . Minute virus of mice (MVMp) infection and NS1 expression induce p53 independent apoptosis in transformed rat fibroblast cells. Virology. 2011; 412(1):233-43. DOI: 10.1016/j.virol.2010.12.035. View

20.

Paglino J, Tattersall P . The parvoviral capsid controls an intracellular phase of infection essential for efficient killing of stepwise-transformed human fibroblasts. Virology. 2011; 416(1-2):32-41. PMC: 3112476. DOI: 10.1016/j.virol.2011.04.015. View